Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Victor Augusto Teixeira LeocádioDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-0260-353X
Isabela L MirandaDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
Martha H C MagalhãesDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
Valtair Severino Dos Santos JúniorDepartamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-4291-8624
José Eduardo GoncalvesDepartamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
Renata Barbosa OliveiraDepartamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0001-5884-2567
Vinicius Gonçalves MaltarolloDepartamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0001-9675-5907
Rafael Wesley BastosCentro de Biociências, Universidade Federal do Rio Grande do Norte, Natal 59078-970, Brazil.
Gustavo GoldmanFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto 14040-903,Brazil.
Susana JohannDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
Nalu Teixeira de Aguiar PeresDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
Daniel de Assis SantosDepartamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-1108-5666
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Cryptococcosis is a severe fungal infection primarily caused by two encapsulated yeasts:
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Thiazole Derivatives as Promising Candidates for Cryptococcosis Therapy. · full record | OpenQuestion